IMAC

Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company

Retrieved on: 
Tuesday, May 23, 2023
Drug development, Therapy, Cancer, Head, Medicine, Prostate, Biomarker, Neck, Proteomics, Lung, Medicare, Mergers and acquisitions, Patient, OTC, Biology, LDT, Oncology, FDA, Breast cancer, IMAC, BACK, Pharmaceutical industry, Medical imaging

Golden, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”), today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.

Key Points: 
  • Golden, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies , Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”), today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company.
  • If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.
  • The Theralink® Test for Advanced Breast Cancer measures the abundance and activation of 32 clinically actionable biomarkers.
  • The test reports which of the 32 biomarkers are highly expressed or activated and the FDA-approved therapeutics that target them.

BACK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of IMAC Holdings, Inc. Is Fair to Shareholders

Retrieved on: 
Tuesday, May 23, 2023
Class Action Lawsuit, Professional Services, Legal, Fraud, Advertising, IMAC, BACK, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of IMAC Holdings, Inc. (NASDAQ: BACK) and Theralink Technologies, Inc. is fair to IMAC shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of IMAC Holdings, Inc. (NASDAQ: BACK) and Theralink Technologies, Inc. is fair to IMAC shareholders.
  • The investigation concerns whether IMAC and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for IMAC shareholders; and (2) disclose all material information necessary for IMAC shareholders to adequately assess and value the merger consideration.
  • On behalf of IMAC shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company

Retrieved on: 
Tuesday, May 23, 2023
Drug development, Therapy, Cancer, Tripura Merger Agreement, Head, Medicine, Prostate, Biomarker, Neck, Proteomics, Lung, Medicare, Mergers and acquisitions, Patient, OTC, Biology, LDT, Oncology, FDA, Breast cancer, IMAC, BACK, Pharmaceutical industry, Medical imaging

GOLDEN, Colo., May 23, 2023 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: THER) ("Theralink") and IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC"), today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the "Merger") in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company. If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.

Key Points: 
  • If completed, the Merger will result in a combined company that will focus on end-to-end proteomics testing, one of the most robust and growing areas of medicine.
  • The Theralink® Test for Advanced Breast Cancer measures the abundance and activation of 32 clinically actionable biomarkers.
  • The test reports which of the 32 biomarkers are highly expressed or activated and the FDA-approved therapeutics that target them.
  • We are excited to be making that a reality by embarking on our next chapter with this merger with IMAC."

IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update

Retrieved on: 
Saturday, April 1, 2023
Backspace, Letter, Obesity, Face, Stroke, Data collection, G&A, Rehabilitation, The Twelve Months, Sale, Movement, Trial of the century, Pain, Clinical trial, Acquisition, Diagnosis, Neuro, IMAC, BACK, Pharmaceutical industry, Medical device, Cryptocurrency, Hypokinesia

BRENTWOOD, Tenn., March 31, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today reported its financial results for the year ended December 31, 2022.

Key Points: 
  • BRENTWOOD, Tenn., March 31, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today reported its financial results for the year ended December 31, 2022.
  • Sold one clinic and closed four small clinics while reducing corporate salaries and headcount.
  • Executed a Letter of Intent to merge with Brain Scientific, Inc.
    “We ended 2022 and started 2023 by taking steps to right-size the company in anticipation of executing a strategic merger.
  • For the year ended December 31, 2022, the Company reported cash and cash equivalents of $0.8 million, compared with approximately $7.1 million as of December 31, 2021.

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

Retrieved on: 
Monday, March 20, 2023
CE, Letter, Stroke, DSM-IV codes, Rehabilitation, Neurology, Certification, Alzheimer's disease, Science, Patient, EEG, Hypokinesia, Diagnosis, Growth, Neuro, FDA, IMAC, BACK, Medical imaging, Medical device

BRENTWOOD, Tenn. and LAKEWOOD RANCH, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC”)(Nasdaq: BACK), a regenerative rehabilitation company focused on treating musculoskeletal and neurodegenerative disease, and Brain Scientific, Inc. (“Brain Scientific”)(OTCQB:BRSFD), a Florida-based applied science technology company, jointly announced today that they have executed a binding Letter of Intent to combine companies in a strategic merger-of-equals (the “Transaction”).

Key Points: 
  • Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.
  • Hassan Kotob, Chief Executive Officer of Brain Scientific, is expected to serve as Chairman and CEO of the combined company.
  • Brain Scientific’s disposable NeuroCap and portable NeuroEEG enable neurologists to save time, see more patients, and eliminate contamination risks.
  • Olshan Frome Wolosky LLP is serving as legal counsel for IMAC, and Lucosky Brookman LLP is serving as legal counsel for Brain Scientific.

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

Retrieved on: 
Monday, March 20, 2023
CE, Letter, DSM-IV codes, Rehabilitation, Neurology, Certification, Science, Patient, EEG, Hypokinesia, Diagnosis, Growth, Neuro, FDA, IMAC, BACK, Medical imaging, Medical device

Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.

Key Points: 
  • Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.
  • Hassan Kotob, Chief Executive Officer of Brain Scientific, is expected to serve as Chairman and CEO of the combined company.
  • Brain Scientific’s disposable NeuroCap and portable NeuroEEG enable neurologists to save time, see more patients, and eliminate contamination risks.
  • “We believe that a Brain Scientific and IMAC merger would allow us to accelerate our growth and expand into new channels and markets to provide those suffering from neurological disorders with the best care possible.”

IMAC Holdings, Inc announces the sale of The BackSpace

Retrieved on: 
Wednesday, March 1, 2023
Sale, BACK, Walmart, IMAC, Backspace

BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health.

Key Points: 
  • BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or the “Company”), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health.
  • The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations.
  • In addition to the sale of The BackSpace, the Company’s Chief Operating Officer, Dr. Ben Lerner, announced his resignation to pursue other interests.
  • The Company will not replace the COO position and Dr. Matt Wallis, President of IMAC, will continue to manage operating responsibilities for the Company’s medical clinic division.

Park Place Technologies Acquires CentricsIT Global Services Division

Retrieved on: 
Thursday, December 8, 2022
Acquisition, DMSO, Park Place, IBM Global Services, Engineering, Equity, Freedom, Discover, Culture, Patrick, Machine learning, GTCR, Project management, CX, Parkview, TPM, Odegaard, Project Management Institute, Charlesbank Capital Partners, Professional services, Automation, PPT, Civil engineering, IMAC

CLEVELAND, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia.

Key Points: 
  • CLEVELAND, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia.
  • CentricsIT customers will gain access to Park Place Technologies’ unique portfolio of products and services, including automated monitoring and managed services.
  • Chris Adams, President and CEO of Park Place Technologies, said in addition to investing in Professional Services, Park Place continues to focus on providing exceptional customer service and support.
  • Park Place’s industry-leading and award-winning services include Park Place Hardware Maintenance™, Park Place Professional Services™, ParkView Managed Services™, Entuity Software™ and Curvature Hardware sales.

Park Place Technologies Acquires CentricsIT Global Services Division

Retrieved on: 
Tuesday, December 6, 2022
Acquisition, DMSO, Park Place, IBM Global Services, Engineering, Equity, Freedom, Discover, Culture, Patrick, Machine learning, GTCR, Project management, CX, Parkview, TPM, Odegaard, Project Management Institute, Charlesbank Capital Partners, Professional services, Automation, PPT, IMAC

CLEVELAND, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia.

Key Points: 
  • CLEVELAND, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia.
  • CentricsIT customers will gain access to Park Place Technologies’ unique portfolio of products and services, including automated monitoring and managed services.
  • Chris Adams, President and CEO of Park Place Technologies, said in addition to investing in Professional Services, Park Place continues to focus on providing exceptional customer service and support.
  • Park Place’s industry-leading and award-winning services include Park Place Hardware Maintenance™, Park Place Professional Services™, ParkView Managed Services™, Entuity Software™ and Curvature Hardware sales.

IMAC Holdings Announces Third Quarter Results

Retrieved on: 
Tuesday, November 15, 2022
Marketing, BACK, Weight loss, Pain, Arthralgia, Patient, Sports medicine, Movement, Ageing, Inflammation, Rehabilitation, Neurodegeneration, Health, IMAC, USDA, Backspace, Trial of the century, Obesity, Human back, Renewable energy, Video game, Pharmaceutical industry, Hypokinesia, Walmart

BRENTWOOD, Tenn., Nov. 15, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” “BACK” or the “Company”), today reported its preliminary financial results for the third quarter ended September 30, 2022.

Key Points: 
  • BRENTWOOD, Tenn., Nov. 15, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc.(Nasdaq:BACK) (IMAC BACK or the Company), today reported its preliminary financial results for the third quarter endedSeptember 30, 2022.
  • Financial and Corporate Highlights from Q3 2022:
    Total Revenue increased 9% to $3.78 million, compared with $3.48 million in the third quarter 2021
    The BackSpace grew visits 1,818% and 28% for the comparable and sequential quarter, respectively
    The entire IMAC team worked hard to produce a solid quarter and achieved our sixth consecutive comparable quarter of revenue growth.
  • Additionally, we were able to reduce liabilities by $1 million during the quarter and finish the quarter with immaterial note payable balances, said Jeffrey Ervin, CEO of BACK.
  • As a result, we implemented a medical weight loss and hormone optimization service during the quarter which we anticipate generating material revenue during the first quarter, 2023.